H1N1 influenza:
Responding to a pandemic

As H1N1 flu continues to make headlines across the world, GlaxoSmithKline is responding to the flu pandemic.

GSK is investing in the development of vaccines for the influenza A (H1N1) strain of flu and the increased production of the anti-viral Relenza through its own manufacturing facilities and through partnerships with other companies.

Announcements